Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
Conditions: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Biphenotypic Acute Leukemia; Undifferentiated Leukemia; Prolymphocytic Leukemia; Myelodysplastic Syndromes; Chronic Myelogenous Leukemia; Myeloproliferative Neoplasm; Relapsed Large Cell Lymphoma; Man tle Cell Lymphoma; Hodgkin Lymphoma; Burkitt Lymphoma; Relapsed T-Cell Lymphoma; Relapsed Chronic Lymphocytic Leukemia; Relapsed Small Lymphocytic Lymphoma; Relapsed Marginal B-cell Lymphoma; Relapsed Follicular Lymphoma; Lymphoplasmacytic Lymphoma Interventions: Drug: Fludarabine; Drug: Melphalan; Radiation: Total Body Irradiation Sponsor: H. Lee Moffitt Cancer Center and Research Institute Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Burkitt Lymphoma | Cancer | Cancer & Oncology | Hematology | Leukemia | Lymphoma | Research